SCHEMBL17756338

SCHEMBL17756338

Cc1ccc(S(=O)(=O)n2ccc3c(-c4ccc(C(=O)N(C)C)cc4)cn(C)c(=O)c32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 9/20 0.52
▸ CECR2 Q9BXF3 3/20 0.50
▸ SCN9A Q15858 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TAF1 P21675 2/20 0.39
▸ TRIM24 O15164 1/20 0.39
▸ SMARCA2 P51531 1/20 0.39
▸ SMARCA4 P51532 1/20 0.39
▸ BRPF1 P55201 1/20 0.39
▸ EP300 Q09472 1/20 0.39
▸ PBRM1 Q86U86 1/20 0.39
▸ CREBBP Q92793 1/20 0.39
▸ BRD9 Q9H8M2 1/20 0.39
▸ BAZ2B Q9UIF8 1/20 0.39
▸ BAZ2A Q9UIF9 1/20 0.39
▸ VEGFA P15692 1/20 0.38
▸ EGLN1 Q9GZT9 1/20 0.38
▸ PTPN11 Q06124 1/20 0.37
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17755641 0.86 BRD4 (0.52) BRD4SCN9AL3MBTL1TRIM24PTPN11
SCHEMBL31590648 0.83 BRD4 (0.70) BRD4L3MBTL1
SCHEMBL31589671 0.83 BRD4 (0.56) BRD4L3MBTL1LMNA
SCHEMBL31589747 0.81 BRD4 (0.55) BRD4L3MBTL1LMNA
SCHEMBL31590455 0.81 BRD4 (0.58) BRD4L3MBTL1BRD9
SCHEMBL31590489 0.80 BRD4 (0.56) BRD4L3MBTL1BRD9PTPN11
SCHEMBL17748911 0.79 BRD9 (0.57) BRD4CECR2TAF1TRIM24SMARCA2
SCHEMBL19639061 0.77 BRD9 (0.52) BRD4L3MBTL1TAF1BRD9SMN1; SMN2
SCHEMBL19640352 0.76 BRD4 (0.59) BRD4CECR2TAF1TRIM24SMARCA2
SCHEMBL30073414 0.76 BRD4 (0.59) BRD4CECR2TAF1TRIM24SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3218374-B1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH INC (US) 2021-12-29 — — EP disclosed
US-10150767-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2018-12-11 — — US disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 — — US disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 — — US disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 — — US disclosed
WO-2016077380-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH, INC. (US) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRPF3 BRD4 1/4885CECR2 246/4885SCN9A 1663/4885
US-10150767-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRPF3 BRD4 1/4885CECR2 246/4885SCN9A 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback